Reply to R. Meisel
- PMID: 37043706
- PMCID: PMC10256417
- DOI: 10.1200/JCO.23.00508
Reply to R. Meisel
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
No potential conflicts of interest were reported.
Comment on
-
Secondary Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease Inform Gene Therapy Approaches.J Clin Oncol. 2023 Jun 10;41(17):3272-3273. doi: 10.1200/JCO.23.00403. Epub 2023 Apr 12. J Clin Oncol. 2023. PMID: 37043702 No abstract available.
References
-
- Meisel R: Secondary malignancies after allogeneic hematopoietic stem cell transplantation for sickle cell disease inform gene therapy approaches. J Clin Oncol 41:3272-3273, 2023 - PubMed
-
- Stubbins RJ, Platzbecker U, Karsan A: Inflammation and myeloid malignancy: Quenching the flame. Blood 140:1067-1074, 2022 - PubMed
Publication types
LinkOut - more resources
Full Text Sources